BioInvent Announces Promising Initial Efficacy Data from Triple Combination Arm of BI-1206, Rituximab and Calquence for the Treatment of non-Hodgkin's Lymphoma
LUND, SWEDEN / ACCESSWIRE / January 8, 2025 / BioInvent International (STO:BINV) The first two patients enrolled in the Phase 2a study triplet arm combining BI-1206 with rituximab and Calquence® responded to treatment One complete response (CR) and one partial response (PR) The treatment has been well-tolerated with no safety or tolerability concerns Study now expanding to additional clinical investigational sites and patient enrollment on track with further Phase 2a results expected by mid-2025 BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces promising initial clinical response data from the two enrolled patients in the triple combination arm of the Phase 1/2a study of its anti-FcyRIIB antibody, BI-1206, combined with rituximab and AstraZeneca's Bruton's tyrosine kinase (BTK) inhibitor Calquence® (acalabrutinib), in non-Hodgkin's lymphoma (NHL). The preliminary data demonstrates that the combination treatment is well tolerated with the two enrolled patients already showing clinical responses.
BINV: Brandes, The Iconic Value Stock Investor, In ETF Form
Brandes International might as well use the tag line "we buy ugly stocks." They are a deep contrarian value manager. The firm's success dates back to last century, and it investment success over the decades made it founder a billionaire philanthropist. Top value investors like Charles Brandes and John Templeton focused on buying portfolios of non-US stocks with low turnover for long-term compounding returns.
BioInvent to Present Pipeline Progress on BI-1910 and BT-001 at ESMO
LUND, SWEDEN / ACCESSWIRE / July 22, 2024 / BioInvent International (STO:BINV) Two posters to be presented on early clinical projects from BioInvent's robust pipeline totaling six clinical programs: Progress with the Phase 1 trial studying BI-1910 as single agent in solid tumors Initial clinical data from the BT-001 Phase 1 study evaluating the candidate both as single agent and in combination with KEYTRUDA® (pembrolizumab) in patients with solid tumors European Society for Medical Oncology (ESMO 2024) to be held September 13-17, 2024 BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, announced abstracts for BI-1910 and BT-001 have been selected for presentation at ESMO 2024, being held in Barcelona, Spain from September 13th to 17th, 2024. BI-1910 is a monoclonal antibody, a TNFR2 agonist, currently enrolling patients in the monotherapy part of the ongoing Phase 1/2a study in patients with advanced solid tumors.
